T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1101
DXC Technology
DXC
$1.71B
| $8.24M | ﹤0.01% |
308,435
+6,316
| +2% | +$157K |
|
1102
Aura Biosciences
AURA
$802M
| $8.22M | ﹤0.01% |
665,528
-45,077
| -6% | -$482K |
|
1103
Autoliv
ALV
$8.85B
| $8.11M | ﹤0.01% |
95,351
+41,748
| +78% | +$3.62M |
|
1104
Sprott Physical Gold and Silver Trust
CEF
$8.32B
| – | – |
0
| – | – |
|
1105
nCino
NCNO
$2.08B
| $7.81M | ﹤0.01% |
259,124
-703
| -0.3% | -$17.9K |
|
1106
Timken Company
TKR
$9.03B
| $7.79M | ﹤0.01% |
85,060
+6,830
| +9% | +$539K |
|
1107
C4 Therapeutics
CCCC
$502M
| $7.78M | ﹤0.01% |
2,828,605
-46,769
| -2% | -$150K |
|
1108
NorthWestern Energy
NWE
$4.34B
| $7.75M | ﹤0.01% |
136,435
+15,562
| +13% | +$910K |
|
1109
First Citizens BancShares
FCNCA
$25.6B
| $7.64M | ﹤0.01% |
5,950
+16
| +0.3% | +$18.5K |
|
1110
Toyota
TM
$223B
| $7.61M | ﹤0.01% |
47,323
+2,408
| +5% | +$346K |
|
|
BCYC
1111
Bicycle Therapeutics
BCYC
$284M
| $7.59M | ﹤0.01% |
297,285
-20,791
| -7% | -$483K |
|
1112
Albertsons Companies
ACI
$5.83B
| $7.58M | ﹤0.01% |
347,577
+213,485
| +159% | +$4.44M |
|
1113
MACOM Technology Solutions
MTSI
$23.7B
| $7.58M | ﹤0.01% |
115,704
-3,170,831
| -96% | -$192M |
|
|
CMA
1114
DELISTED
Comerica
CMA
| $7.58M | ﹤0.01% |
178,939
| – | – |
|
1115
Silicon Laboratories
SLAB
$7.3B
| $7.57M | ﹤0.01% |
47,954
-2,753
| -5% | -$416K |
|
1116
Meritage Homes
MTH
$4.75B
| $7.55M | ﹤0.01% |
106,070
+336
| +0.3% | +$21.1K |
|
1117
Alignment Healthcare
ALHC
$2.8B
| $7.52M | ﹤0.01% |
1,307,287
-70,170
| -5% | -$454K |
|
1118
Owens Corning
OC
$12.3B
| $7.51M | ﹤0.01% |
57,548
+92
| +0.2% | +$10.1K |
|
1119
Ziff Davis
ZD
$1.92B
| $7.49M | ﹤0.01% |
106,840
-131,539
| -55% | -$9M |
|
1120
Okta
OKTA
$25.6B
| $7.46M | ﹤0.01% |
107,611
-12,650
| -11% | -$961K |
|
1121
TG Therapeutics
TGTX
$7.58B
| $7.4M | ﹤0.01% |
298,039
+223,545
| +300% | +$5.77M |
|
1122
Mohawk Industries
MHK
$9.27B
| $7.36M | ﹤0.01% |
71,301
-1,446,556
| -95% | -$142M |
|
1123
Vesta Real Estate
VTMX
$3.14B
| $7.36M | ﹤0.01% |
+228,303
| New | +$7.36M |
|
|
AL
1124
DELISTED
Air Lease Corp
AL
| $7.29M | ﹤0.01% |
174,118
-6,969
| -4% | -$276K |
|
1125
ING
ING
$102B
| $7.28M | ﹤0.01% |
540,435
+25,788
| +5% | +$330K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.